Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 19/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28689541 | 1.00 | RIPK1 (0.51) | RIPK1ALDH1A1 | |
| SCHEMBL20161261 | 1.00 | RIPK1 (0.51) | RIPK1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28469788 | 0.98 | RIPK1 (0.50) | RIPK1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL23801079 | 0.88 | RIPK1 (0.52) | RIPK1 | |
| SCHEMBL28476136 | 0.82 | RIPK1 (0.54) | RIPK1ALDH1A1 | |
| SCHEMBL28629177 | 0.81 | RIPK1 (0.55) | RIPK1ALDH1A1 | |
| SCHEMBL28938984 | 0.81 | ALDH1A1 (0.43) | RIPK1ALDH1A1 | |
| SCHEMBL30166293 | 0.81 | RIPK1 (0.55) | RIPK1ALDH1A1 | |
| SCHEMBL28971796 | 0.77 | RIPK1 (0.53) | RIPK1ALDH1A1 | |
| SCHEMBL22638823 | 0.76 | RIPK1 (0.51) | RIPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110769853-B | Treatment of male aging | 北京生命科学研究所 | 2022-06-03 | — | — | CN | claimed |
| CN-112370452-A | Heterocyclic amides as kinase inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-02-19 | — | — | CN | claimed |
| CN-107624111-B | Heterocyclic amides as kinase inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-11-03 | — | — | CN | claimed |
| CN-110769853-A | Treatment of male aging | 北京生命科学研究所 | 2020-02-07 | — | — | CN | claimed |
| CN-115697991-B | Piperazine cyclic ureas | 维泰瑞隆有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-113767092-B | Di-heterocyclic carbonyl substituted dihydropyrazoles, their preparation and their use in medicine | 劲方医药科技(上海)有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-116496256-A | Carbonyl bridged heterocyclic compound, and composition and application thereof | 北京赛特明强医药科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-20230120185-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-04-20 | — | — | US | disclosed |
| CN-115697991-A | Piperazine cyclic ureas | 维泰瑞隆有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115605463-A | Inhibitors of receptor interacting protein kinase I for the treatment of diseases | 德州大学系统董事会（US） | 2023-01-13 | — | — | CN | disclosed |
| US-11485710-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-11-01 | — | — | US | disclosed |
| CN-110769853-B | Treatment of male aging | 北京生命科学研究所 | 2022-06-03 | — | — | CN | disclosed |
| WO-2020224656-A1 | BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 劲方医药科技(上海)有限公司 | 2020-11-12 | — | — | WO | disclosed |
| CN-107624111-B | Heterocyclic amides as kinase inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-11-03 | — | — | CN | disclosed |
| US-10590085-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-17 | — | — | US | disclosed |
| CN-110769853-A | Treatment of male aging | 北京生命科学研究所 | 2020-02-07 | — | — | CN | disclosed |
| CN-110573504-A | heterocyclic amides as kinase inhibitors | 葛兰素史克知识产权开发有限公司 | 2019-12-13 | — | — | CN | disclosed |
| US-20180134665-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-05-17 | — | — | US | disclosed |
| CN-1014245-B | PREPN. OF PYRAZOLINE DERIVATIVES | MITSUI TOATSU CHEMICALS (JP) | 1991-10-09 | — | — | CN | disclosed |
| CN-88103735-A | It is the medicine of active ingredient treatment cerebrovascular disease that new pyrazoline derivative reaches with this compound | — | 1988-12-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590085-B2 | Heterocyclic amides as kinase inhibitors | MAP3K19, MAP3K20, MAP3K1 | RIPK1 414/4885ALDH1A1 1542/4885 |
| US-20230120185-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K1 | RIPK1 405/4885ALDH1A1 1576/4885 |
| US-11485710-B2 | Heterocyclic amides as kinase inhibitors | MAP3K19, MAP3K20, MAP3K1 | RIPK1 405/4885ALDH1A1 1576/4885 |
| US-20180134665-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K1 | RIPK1 414/4885ALDH1A1 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.